George, S., Bauer, S., Doi, T., Heinrich, M. C., Hua, L., Leu, K., Hernandez, N. R., Razak, A. R. A., Schmidt, H., Shen, L., Schöffski, P. (2026). StrateGIST 3: A randomized, phase 3 study of velzatinib (IDRX-42) versus sunitinib in patients with advanced gastrointestinal stromal tumors after imatinib therapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps11588